Hanmi Pharmaceutical Company Limited
Hanmi Pharmaceutical Company Limited sponsors 25 registered US clinical trials on ClinicalTrials.gov, 7 of them currently recruiting, and 15 completed. 1 of these trials are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 3 trials.
Trial Pipeline
25 total, page 1 of 1
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
NCT07527650
Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus
NCT07205900
A Single Ascending Dose Study of HM17321 in Healthy Adult Participants
NCT07219589
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
NCT06724016
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
NCT06234397
HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
NCT04732416
Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects
NCT04775706
Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects
NCT04505436
A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.
NCT06481098
Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function
NCT05711381
Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities
NCT04167553
A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD
NCT03744182
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)
NCT03374241
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
NCT03353350
Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus
NCT03332836
Molar Potency Study of HM12460A in Healthy Subjects
NCT03330314
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
NCT02485652
Molar Potency Study of HM12470 in Healthy Subjects
NCT03330327
Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
NCT02081118
Effect of LAPS-Exendin on Body Weight in Obese Population
NCT02075281
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
NCT02057172
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A
NCT01724814
Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
NCT01452451
Safety and PK of HM10460A (HNK460) in Healthy Adult Japanese and Caucasian Subjects
NCT01037543
A Study of HM10760A (Long-acting Erythropoietin) in Healthy Adult Caucasian and Japanese Subjects
NCT01030315
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 10 |
| Phase 3 | 1 |
Therapeutic Areas
What the Pipeline for Hanmi Pharmaceutical Company Limited Shows
According to the ClinicalTrials.gov registry, Hanmi Pharmaceutical Company Limited is linked to 25 US clinical trials across every stage of research activity. Of those, 7 studies are currently recruiting, about 28% of the sponsor's indexed portfolio, and 15 are already marked complete, representing roughly 60% of the total.
The phase mix for Hanmi Pharmaceutical Company Limited reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 24 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for Hanmi Pharmaceutical Company Limited is Obesity with 3 linked trials, and 9 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.